Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag

Moderna and Merck receive FDA breakthrough status for personalized cancer vaccine

CNBC's Meg Tirrell reports on news from Moderna and Merck.

Moderna’s skin cancer therapy receives breakthrough tag after promising study results

Moderna Inc has said its experimental personalised mRNA skin cancer vaccine in combination with Merck drug Keytruda has received breakthrough therapy designation from US regulators as an additional treatment for high risk patients.

Moderna-Merck gets USFDA Breakthrough Therapy Designation for personalized mRNA cancer vaccine in combination with KEYTRUDA to treat high-risk melanoma

Cambridge: Moderna, Inc. and Merck have announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted...

Moderna, Merck's mRNA cancer vaccine, Keytruda combo gets FDA breakthrough therapy tag

The U.S. Food and Drug Administration ((FDA)) granted breakthrough therapy designation to Moderna (MRNA) and Merck's (MRK) personalized mRNA cancer vaccine mRNA-4157/V940, in...

Moderna's skin cancer therapy receives breakthrough tag

Moderna's mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine